

Media Outlet: Pharmaceutical Executive

Date: 11<sup>th</sup> September

URL: <http://www.pharmexec.com/india-reports-surge-pharma-market>

The screenshot shows the PharmExec.com website interface. At the top, there is a navigation bar with the site logo and a search box. Below the navigation bar, there are links for 'Magazine Topics', 'Events', 'Resources', 'Subscribe', 'Advertise', and 'Contact Us'. A 'SUBSCRIBE' button is prominently displayed. The main content area features the article title 'India Reports Surge in Pharma Market' with a sub-headline 'Market'. The article is dated 'Sep 11, 2015' and is attributed to 'Pharmaceutical Executive Editors'. The text of the article reports that the India Brand Equity Foundation (IBEF) estimates the Indian domestic pharma market at INR 90,400 crore (US\$ 15 bn) for FY15, a 12% increase. It also lists the top 20 companies, with Macleoids leading at 23.4% growth, followed by Intas (21.3%), Cipla (19.7%), Glenmark (19.4%), and Mankind (19.3%). The article mentions that pharma exports reached US\$ 15.3 bn in 2014-15, up from \$ 5.78 bn in 2013. A sidebar on the left contains a 'Most Read' section with links to 'Current Issue', 'Top Features', 'New & Noteworthy', 'Washington Report', and 'Webcasts'. A 'Share' button and social media links for LinkedIn and Twitter are also visible. A promotional banner for 'HAL & PAIN MODELING SEPT 23 CHICAGO' is shown on the right. The footer includes the CPhI worldwide logo.

## India Reports Surge in Pharma Market

Sep 11, 2015

By Pharmaceutical Executive Editors

The India Brand Equity Foundation (IBEF) reports that the Indian domestic pharma market is estimated at INR 90,400 crore (US\$ 15 bn), ending FY15 with a growth of 12%.

India's top 20 companies are said now to account for 64% of the domestic market. Eight out of the top 20 are reportedly growing faster than the market, with Macleoids topping the list with 23.4% growth followed by Intas with 21.3%, Cipla 19.7% Glenmark over 19.4% growth and Mankind 19.3%. India's pharma exports stood at US\$ 15.3 bn in 2014-15. M&A activity in the industry accounted for \$ 5.78 bn an increase of around 44.5% in comparison to 2013.

IBEF points to public-private partnerships, an increased penetration of healthcare facilities in non-metro cities, involvement of multinationals in setting up facilities in the country, and establishment of educational institutions as the prime reasons for India's pharma surge.

Further, it reports that India is expected to grab "at least a 20-25 percent share of the global market share in biosimilars in the next five years".